Analysis Of Clinical Data Of Endometrial Cancer Patients With Diabetes

Objective Through the comparative analysis of clinical data of patients with endometrial cancer with diabetes and patients with simple endometrial cancer,to explore the impact of diabetes on the biological behavior of tumors in patients with endometrial cancer and its clinical significance,in order to better guide clinical work.Method A total of 110 patients diagnosed with endometrial adenocarcinoma who were admitted to the Department of Gynecology,Binzhou Medical College Hospital from January 2016 to December 2019 were collected and divided into endometrial cancer and diabetes groups according to whether they had diabetes.Observation group)51 cases and 59 cases of simple endometrial cancer group(control group).General information,clinical manifestations,postmenopausal endometrial thickness,tumor markers before surgery,degree of tissue differentiation,and immunohistochemistry And so on for statistical analysis.Based on the above grouping,sub-grouping was performed according to the clinical pathological stage,and the data were statistically analyzed.The data were divided into two groups:stage Ⅰ endometrial cancer and stage Ⅱ and above endometrial cancer.The data obtained were all using SPSS 26.0 statistical software deal with.The measurement data is first tested for normality.If it meets the normal distribution or approximate normal distribution,the group data should be tested by t or multiple groups of data should be analyzed by single factor analysis of variance;if it is not consistent with the normal distribution,the approximate normal distribution and For non-count data,non-parametric tests are performed(2 independent sample tests or K independent sample tests);chi-square test is used for count data.Statistically significant with P<0.05.Result 1.The average age of the observation group and the control group were 55.84±8.97 years and 54.12±7.33 years respectively.There was no significant difference between the two groups;the average age of patients with stage Ⅰ endometrial cancer in the observation group and control group was 56.21±9.28 years old,54.26±7.65 years old respectively.the difference between the two groups was not statistically significant;the average age of patients with stageⅡ or higher endometrial cancer in the observation group and the control group was 54.77±8.25 years old,53.75±6.59 years old,two There was no statistically significant difference between the groups.The mean menopausal age of the patients in the observation group and the control group were 50.71±4.50 years and 50.24±3.08 years respectively.There was no significant difference between the two groups(t=0.502,P=0.617>0.05);the observation group and the control group were The average menopausal age of patients with intermediate stage Ⅰendometrial cancer was 51.12±4.77 years and 49.88±3.12 years.There was no significant difference between the two groups(t=1.12 P=0.276>0.05);in the observation group and the control group,The average menopausal age of patients with stage Ⅱ and above endometrial cancer was 49.56±3.58 years and 51.57±2.76 years.There was no significant difference between the two groups(t=-1.231 P=0.239>0.05).2.The clinical manifestations(vaginal bleeding,vaginal fluid,abdominal pain,leucorrhea abnormality,uterine prolapse)of the two groups of patients were not statistically significant(P>0.05).3.The median and quartiles of postmenopausal endometrial thickness in the observation group and the control group were 14(10,1 7)mm,and 12(10,14)mm,respectively.There was no significant difference between the two groups(Z=-1.521 P=0.128>0.05).The postmenopausal endometrial thickness of patients with stage I endometrial cancer in the observation group and the control group was 13(10,18)mm and 12(10,13.25)mm,respectively,with no significant difference(Z=·1.457 P=0.145>0.05);the postmenopausal endometrial thickness of patients with stage Ⅱ and above endometrial cancer in the observation group and the control group was 15(10,16.5)mm and 13(10,15)mm,respectively.Not statistically significant(Z=-0.748 P=0.455>0.05).4.The CA125 level in the observation group was higher than that in the control group,with median values of 25.09 U/ml and 19.21 U/ml,the differences were statistically significant(P<0.05).The CA125 levels of patients with stage Ⅰ endometrial cancer in the observation group and the control group were 19.5U/ml vs 17.56U/ml,respectively,and the difference was not statistically significant.The CA125 in the observation group was higher than the CA125 in the control group,the median The numbers were 35.93 U/ml vs 21.67 U/ml,and the difference was statistically significant(P<0.05).The CA199 level in the observation group was higher than that in the control group,with median values of 24.06 U/ml vs 13.06 U/ml,the difference was statistically significant(P<0.05).The level of CA199 in stage Ⅰ endometrial cancer in the observation group was higher than that in the control group,with a median of 19.58 U/ml vs 17.56 U/ml,the difference was statistically significant(P<0.05).The level of CA199 in stage Ⅱ and above endometrial cancer was higher than that in stage Ⅰ and above in the control group,with a median of 24.06 U/ml vs 15.09 U/ml,the difference was statistically significant(P<0.05)).The HE4 level in the observation group was higher than that in the control group,with median values of 97.1 pmol/L vs 68.70 pmol/L,the differences were statistically significant(P<0.05).The HE4 level of stage Ⅰ endometrial cancer in the observation group was higher than that of stage Ⅰ endometrial cancer in the control group,with a median of 89.35pmol/L vs 68.7pmol/L,the difference was statistically significant(P<0.05);The median of stage II and above endometrial cancer HE4 in the observation group and the control group was 102.00 pmol/L vs 80.55 pmol/L.There was no significant difference..5.The degree of differentiation(highly differentiated,moderately differentiated,and poorly differentiated)of the tissues in the observation group and the control group accounted for the percentage in the group,respectively:high differentiation:35.29%vs 45.76%,medium differentiation:54.90%vs 45.76%,and low differentiation:9.80%vs 8.47%),the difference was not statistically significant.6.The positive rates of ER in the observation group and the control group were 86.3%vs 79.7%,and the two groups were statistically analyzed,and the differences were not statistically significant.The ER positive rates of stage Ⅰ endometrial cancer in the observation group and the control group were 86.8%vs 81.4%,respectively.There was no significant difference between the two groups;the ER of stage Ⅱ and above endometrial cancer in the observation group and the control group was not significant.The positive rates were 84.6%vs 75%.There was no significant difference between the two groups.The positive rates of PR in the observation group and the control group were 84.3%vs 83.1%,and there was no significant difference between the two groups.The PR positive rates of stage Ⅰ endometrial cancer in the observation group and control group were 81.6%and 88.4%,respectively.There was no significant difference between the two groups;The positive rates were 84.6%vs 68.8%,and there was no significant difference between the two groups.The positive rates of P53 in the observation group and the control group were 72.5%vs 57.6%,respectively.There was no significant difference between the two groups.The positive rates of P53 in patients with stage Ⅰ endometrial cancer in the observation group and the control group were 68.4%vs 58.1%,respectively.There was no statistically significant difference between the two groups.The positive rates of P53 were 84.6%vs 56.3%.There was no significant difference between the two groups.The median Ki-67 in the observation group and the control group were 40%vs 30%.There were statistical differences between the two groups.Significance(P<0.05).The median Ki-67 of stage Ⅰendometrial cancer in the observation group and the control group were 40%vs 30%,respectively,and there was a statistically significant difference between the two groups(P<0.05);stage Ⅱ in the observation group and the control group The median Ki-67 of endometrial cancer and above was 50%vs 37.5%,and there was no significant difference between the two groups..Conclusions 1.There is no difference in the age and menopausal age between patients with diabetes and endometrial cancer and those with simple endometrial cancer;2.Diabetes has no effect on the clinical manifestations of patients with endometrial cancer;3.Diabetes has no effect on endometrial thickness in patients with endometrial cancer;4.Diabetes can affect the levels of CA125,CA199,and HE4 in endometrial cancer.Diabetes has a more significant effect on CA125 levels in stage Ⅱ and above endometrial cancer,while HE4 is affected by diabetes in stage Ⅰ endometrial cancer More obviously,Patients with diabetes can also play a role in early detection of endometrial cancer through the combined screening of CA125 and HE4;5.Diabetes has no effect on the degree of tissue differentiation in patients with endometrial cancer;6.Diabetes has no effect on immunohistochemical ER,PR,P53 of endometrial cancer;it has a certain effect on Ki-67,especially in stage Ⅰ endometrial cancer,which indicates that diabetes has a certain effect on the prognosis of EC.